trending Market Intelligence /marketintelligence/en/news-insights/trending/8qidpvz4wnsqirnnvmfseq2 content esgSubNav
In This List

Genocea CFO resigns

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Genocea CFO resigns

Jonathan Poole resigned as CFO of Genocea Biosciences Inc., effective March 23.

Poole resigned to pursue another professional opportunity. He will assist in the transition of the CFO role until his departure.

The company is conducting a search to replace Poole, and pending the conclusion of that search, President and CEO William Clark will assume the duties of principal financial officer and principal accounting officer.

Cambridge, Mass.-based Genocea is a biopharmaceutical company engaged in developing T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer.